ClinicalTrials.gov
public full text
Public Domain
Assess the Oral Bioavailability of New ABT-263 Formulations
This is a randomized, open-label, multicenter crossover study to determine the oral bioavailability of new ABT-263 formulations relative to that of the current ABT-263 formulation being administered in ongoing Phase 1/2a studies. Approximately 36 evaluable subjects with lymphoid malignancies, including chronic lymphocytic leukemia, and solid tumors will be enrolled in this study.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer#992517
- A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors#810101
- PRO1107 in Patients With Advanced Solid Tumors#852344
- Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion#848461
- A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.#836155
Record · ID 880350
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive